Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition is in a strong position with promising pipeline and commercialization plans for its lead product, ZUNVEYL. The company has recorded impressive financial results and continues to advance in its clinical trials, providing important real-world evidence and expanding its commercial opportunities. The recent settlement agreement has streamlined royalty obligations and the addition of Bethany Sensenig as a director brings valuable experience and expertise to the company's leadership team.

Bears say

Alpha Cognition is facing challenges in achieving sales traction for ZUNVEYL, their primary product, due to pricing pressures and potential competition from both generic and branded products. Additionally, setbacks in clinical testing and a medium to long-term dilution risk pose significant risks to the company's prospects. With a total enterprise value of $520M and a price objective of $18 per share, it is evident that the negative outlook on Alpha Cognition's stock is driven by these fundamental risks and uncertainties.

ACOG has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 4 analysts, ACOG has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.